FINHUB Insights

ABBV · Q3 FY25 · Jul 1 – Sep 30, 2025

AbbVie Q3 FY25: where the revenue came from and where it went

AbbVie Q3 FY25: revenue $15.8B (+9% year over year). Net profit $0.2B. Largest cohort Skyrizi $4.7B. The whole income statement as a sankey diagram from the SEC filing.

Period
Jul 1 – Sep 30, 2025
Reported
Nov 4, 2025 10-Q
Sankey diagram of AbbVie's income statement for Q3 FY25: revenue of $15.8 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$15.8B +9% year over year
Gross profit$10.5B 66% margin
Operating profit$1.9B 12% margin
Net profit$0.2B 1% margin

The numbers

All figures in billions of U.S. dollars, for Q3 FY25 (period ends Sep 30, 2025).
ItemValueShare of revenueYear over year
Revenue 15.8 100% +9%
Skyrizi 4.7 30% +47%
Neuroscience 2.8 18% +20%
Other 2.2 14%
Rinvoq 2.2 14% +35%
Oncology 1.7 11%
Aesthetics 1.2 8% −4%
Humira 1 6% −55%
Cost of revenue−5.334%
Gross profit10.566% margin−4pp
SG&A−3.623%−6pp
Other−532%+0pp
Operating profit1.912% margin−14pp
Tax−0.5
Interest & other costs−1.2
Net profit0.21%−10pp
Filing on EDGAR More quarters of ABBV

Source of the numbers: tables in the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

Older quarters